GW Pharmaceuticals plc GWPH said Monday it will obtain exclusive rights for the commercialization of Sativex in the U.K. from Bayer AG BAYRY.
Sativex is an oromucosal spray with the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) in a 1-to-1 ratio.
In the U.S. it is known under the name Nabiximols and is used to help treat spasticity in patients suffering from multiple sclerosis.
The spray was approved by the Medicines and Healthcare products Regulatory Agency back in 2010, and Bayer has seen controlled advertising in the U.K.
GW Pharma will obtain all duties regarding the commercialization of Sativex in the U.K., after the end of the year, and will be in a transitional period until then, according to the company.
GW Pharma’s shares were trading lower by at $100.78 at the time of publication Monday.
Related Links:
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.